Companies › Dr. F. Köhler Chemie
1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Gastroenterology, Other; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Custodiol-N Solution Organ preservation solution for perfusion | – | Phase 3 | Kidney Failure; Heart Transplantation | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06032195 | Custodiol-N Solution | Phase 2 | Heart Transplantation | Other | Jan 2027 |
| NCT03627013 | Custodiol-N Solution | Phase 3 | Kidney Failure | Gastroenterology | Sep 2028 |
No annotated target.
–
Albireo, an Ipsen Company GRIN Therapeutics Getz Pharma Huons Biopharma Neuren Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.